Is Gyre Therapeutics, Inc. (GYRE) Overvalued?
We dive into why Gyre Therapeutics, Inc. (GYRE) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Commentary & Analysis
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.77%
As of Tuesday, August 04, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.77%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.91%
As of Monday, August 03, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.91%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Down 5.68%
As of Wednesday, July 29, Gyre Therapeutics, Inc.’s GYRE share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.22%
As of Monday, July 27, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $732.7 | $292.6 | 41% |
|
| Shares Out (Mil) | 100.6 | 54.4 | 62% |
|
| Institutional Ownership | 58.8% | 93.2% | 38% |
|
| Float (Mil) | 35.9 | 40.2 | 40% |
|
| Beta | 4.81 | 0.94 | 99% |
|
| Avg Daily Volume (000s) | 61 | 544 | 30% |
|
| Price Change (52-week) |
(10.6%) | 59.7% | 35% |
|
| Growth | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.073) | ($0.400) | ($0.235) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (39.2%) | (1,918%) | 7,900% | |
| Financials | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $110 | $37 | 27% |
|
| Net Income (TTM) (Mil) | ($21) | ($43) | 23% |
|
| EPS (TTM) | ($0.212) | ($1.400) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($31) | 25% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $2 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $698 | $164 | 38% |
|
| Valuation | GYRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.77 | 2.83 | 84% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.8% | 64.2% | 95% |
|
| Net Margin | (19.3%) | (75.9%) | 17% |
|
| ROA | (12.1%) | (47.5%) | 24% |
|
| ROE | (21.2%) | (55.0%) | 23% |
|
| Liabilities to Assets | 17.2% | 29.6% | 11% |
|
| F-Score | 1 | 3 | na |
|
Gyre Therapeutics, Inc. did not pass any screens on 8/21/2026.
